387 related articles for article (PubMed ID: 28421342)
1. Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients.
Park YG; Kang S; Kim M; Yoo N; Roh YJ
Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1375-1383. PubMed ID: 28421342
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Selective Retina Therapy for Bevacizumab-Resistant Chronic Central Serous Chorioretinopathy.
Jeon SH; Kim M; Lee J; Roh YJ
Ophthalmologica; 2022; 245(1):91-100. PubMed ID: 34649253
[TBL] [Abstract][Full Text] [Related]
3. Selective Retina Therapy in Acute and Chronic-Recurrent Central Serous Chorioretinopathy.
Framme C; Walter A; Berger L; Prahs P; Alt C; Theisen-Kunde D; Kowal J; Brinkmann R
Ophthalmologica; 2015; 234(4):177-88. PubMed ID: 26368551
[TBL] [Abstract][Full Text] [Related]
4. Selective retina therapy (SRT) in patients with therapy refractory persistent acute central serous chorioretinopathy (CSC): 3 months functional and morphological results.
Büttner M; Luger B; Abou Moulig W; Junker B; Framme C; Jacobsen C; Knoll K; Pielen A;
Graefes Arch Clin Exp Ophthalmol; 2021 Jun; 259(6):1401-1410. PubMed ID: 33205239
[TBL] [Abstract][Full Text] [Related]
5. Selective Retina Therapy in Patients With Chronic Central Serous Chorioretinopathy: A Pilot Study.
Kang S; Park YG; Kim JR; Seifert E; Theisen-Kunde D; Brinkmann R; Roh YJ
Medicine (Baltimore); 2016 Jan; 95(3):e2524. PubMed ID: 26817895
[TBL] [Abstract][Full Text] [Related]
6. The effect of nondamaging subthreshold laser therapy in patients with chronic central serous chorioretinopathy.
Lee SH; Lee J; Kim M; Roh YJ
Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1433-1442. PubMed ID: 38010518
[TBL] [Abstract][Full Text] [Related]
7. Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy.
Yasui A; Yamamoto M; Hirayama K; Shiraki K; Theisen-Kunde D; Brinkmann R; Miura Y; Kohno T
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):243-254. PubMed ID: 27497611
[TBL] [Abstract][Full Text] [Related]
8. Factors Predicting Response to Selective Retina Therapy in Patients with Chronic Central Serous Chorioretinopathy.
Kim M; Jeon SH; Lee JY; Lee SH; Roh YJ
J Clin Med; 2022 Jan; 11(2):. PubMed ID: 35054017
[TBL] [Abstract][Full Text] [Related]
9. Nondamaging photothermal therapy for the retina: initial clinical experience with chronic central serous retinopathy.
Lavinsky D; Palanker D
Retina; 2015 Feb; 35(2):213-22. PubMed ID: 25158944
[TBL] [Abstract][Full Text] [Related]
10. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
[TBL] [Abstract][Full Text] [Related]
12. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
[TBL] [Abstract][Full Text] [Related]
14. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F
Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy.
Oh J; Yoon CK; Kim BH; Yu HG
Korean J Ophthalmol; 2021 Feb; 35(1):51-63. PubMed ID: 33307626
[TBL] [Abstract][Full Text] [Related]
17. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
18. Patient characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage.
van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; MacLaren RE; Querques G; Fauser S; Hoyng CB; Downes SM; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1419-1425. PubMed ID: 31123815
[TBL] [Abstract][Full Text] [Related]
19. Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy.
An SH; Kwon YH
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1489-1496. PubMed ID: 26553195
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
